Fusion Antibodies (LON:FAB) Trading 4% Higher – What’s Next?

Shares of Fusion Antibodies plc (LON:FAB) were up 4% on Tuesday . The stock traded as high as GBX 13 and last traded at GBX 13. Approximately 1,256 shares traded hands during mid-day trading, a decline of 100% from the average daily volume of 454,344 shares. The stock had previously closed at GBX 12.50.

Fusion Antibodies Price Performance

The company has a 50-day moving average of GBX 14.04 and a 200 day moving average of GBX 14.52. The company has a debt-to-equity ratio of 92.42, a quick ratio of 2.36 and a current ratio of 1.80. The firm has a market cap of £16.25 million, a P/E ratio of -8.67 and a beta of 1.22.

About Fusion Antibodies

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.